Tirzepatide Dramatically Outperforms Insulin Glargine for Blood Sugar and Weight in Asia-Pacific Diabetes Trial

SURPASS-AP-Combo was a phase 3, randomized, open-label trial at 66 hospitals in China, South Korea, Australia, and India. Insulin-naive adults with type 2 diabetes uncontrolled on metformin (with or without a sulphonylurea) were randomized 1:1:1:1 to weekly tirzepatide 5mg, 10mg, or 15mg or daily insulin glargine. The primary endpoint was non-inferiority of HbA1c change from baseline to week 40. Key secondary endpoints included superiority testing, HbA1c target achievement rates, and weight change. Of 917 randomized patients, 83.2% were in China.

Type 2 diabetes is particularly prevalent in Asia-Pacific populations, where it often develops at lower BMI than in Western populations. This trial is the first to demonstrate tirzepatide's superiority over insulin specifically in a predominantly Chinese/Asian population. The enormous efficacy gap — tirzepatide reduced HbA1c by up to 2.6 times more than insulin — combined with weight loss instead of weight gain could fundamentally change how diabetes is managed in this region, potentially making insulin a second-choice rather than first-line injectable therapy.

The SURPASS clinical trial program has systematically demonstrated tirzepatide's superiority across multiple comparators — semaglutide, insulin degludec, insulin glargine, and placebo. This Asia-Pacific trial extends the evidence to a population that carries a disproportionate share of the global diabetes burden. The dramatic results raise a fundamental question about the role of insulin in type 2 diabetes management: if a peptide drug delivers better blood sugar control, causes weight loss instead of weight gain, and avoids hypoglycemia, should insulin remain the default injectable escalation?

The open-label design means both patients and investigators knew which treatment was given, which could influence subjective outcomes. Insulin glargine was titrated to target but the specific titration results and final doses are not detailed — undertitration could have disadvantaged the insulin group. The 40-week duration may not capture long-term outcomes. The predominantly Chinese population (83.2%) limits direct generalizability to other Asia-Pacific ethnic groups. Cost-effectiveness was not assessed — tirzepatide is significantly more expensive than insulin glargine.